Companies in #Frontotemporal Dementia

Alector is a clinical-stage biotechnology company developing immuno-neurology therapies for neurodegenerative diseases. Its lead programs target progranulin (PGRN) and TREM2 pathways, with a major 2026 setback when partner GSK walked away from its $700M upfront Alzheimer's collaboration after consecutive clinical failures.

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurologic disorders, and is the successor to EIP Pharma Inc., which launched in 2014 and merged with Diffusion Pharmaceuticals in a transaction completed in late 2023 that created the present Nasdaq-listed entity. The company's sole clinical asset is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of the p38 MAP kinase alpha isoform that targets neuroinflammation-induced synaptic dysfunction rather than amyloid or tau pathology directly. Neflamapimod is in mid-stage development across three distinct indications: dementia with Lewy bodies, where the Phase 2b RewinD-LB study is the lead program; nonfluent variant primary progressive aphasia, a frontotemporal dementia subtype associated with tau pathology; and recovery after ischemic stroke. The company holds an Innovation Passport for neflamapimod in dementia with Lewy bodies under the UK's Innovative Licensing and Access Pathway and receives grant support from the National Institute on Aging for part of the Lewy body dementia program, but has no approved products and no product revenue.

Passage Bio is a clinical-stage genetic medicines company developing gene therapies for central nervous system diseases, built around a research collaboration with the Gene Therapy Program at the University of Pennsylvania's Perelman School of Medicine. Its lead asset, PBFT02, is an AAV1 gene therapy delivering a functional granulin (GRN) gene for the treatment of frontotemporal dementia caused by progranulin deficiency, and is the sole program the company continues to advance after electing to wind down its earlier GM1 gangliosidosis, Krabbe disease and metachromatic leukodystrophy candidates. In June 2026 Passage Bio agreed an all-stock merger with Remix Therapeutics, a clinical-stage company developing small-molecule modulators of RNA processing; on completion the combined company will be renamed Remix Therapeutics, trade on Nasdaq as RMTX, and pursue Remix's lead mRNA degrader REM-422 in adenoid cystic carcinoma and AML/HR-MDS, with legacy Passage Bio holders retaining a minority of the combined entity. The company has flagged going-concern doubt on a declining cash balance and an accumulated deficit of roughly $720 million, and the transaction is subject to a stockholder vote including a proposed reverse stock split.